EDSA Edesa Biotech Inc
Company Analysis
Latest News
🔴 Edesa Biotech is trading 5% down today in a technical pullback after yesterday's rebound
Edesa Biotech is trading 5% down today at $5.09 in a technical pullback following yesterday's rebound, with no fresh company-specific news or filings...
🟢 Edesa Biotech is trading 5.8% up today on technical rebound following recent sharp declines
Edesa Biotech is trading at $5.26 (up 5.8%), staging a recovery after several sharp declines over the past week. • The move appears to be a technical...
🟢 Edesa Biotech is trading 7.1% up today in after-hours technical rebound
Edesa Biotech is trading 7.1% up at $5.32 in after-hours trading, appearing to stage a technical rebound from its previous session decline. The stock is...
🔴 Edesa Biotech is trading 8.2% down today as it reverses a recent unexplained rally
Edesa Biotech is trading 8.2% down at $4.91 as the stock reverses a sharp, low-catalyst spike seen in recent sessions. • There are no new company-specific...
🟢 Edesa Biotech is trading 11.2% up today with no clear catalyst identified
Edesa Biotech is trading 11.2% up at $5.95 in after-hours trading with no clear catalyst identified to explain the move. - No fresh company-specific news,...
🟢 Edesa Biotech is trading 12% up today with no clear news catalyst identified
Edesa Biotech is trading at $5.88 (12% up) after a volatile week with no clear news catalyst identified. • The move follows a 5.3% drop during the July 24...
🔴 Edesa Biotech is trading 5.3% down today amid recent volatility
Edesa Biotech is trading at $5.36 (-5.30%) following a weak start to the July 24 trading session, extending a period of significant price fluctuations. • The...
🟢 Edesa Biotech is trading 14.8% up today on a sharp after-hours bid
Edesa Biotech is trading at $6.50 (+14.84%) following a sharp extended-hours bid despite a lack of company-specific news. • The move appears driven by thin...
🟢 Edesa Biotech is trading 10.1% up
Edesa Biotech is trading at $6.41, up 10.1% from a comparison close of $5.82 during regular trading. This is a price-action follow-up, so a separate catalyst...
🟢 Edesa Biotech is trading 7.2% up today in a technical rebound after yesterday's sharp drop
Edesa Biotech is trading 7.2% up at $6.24, staging a technical rebound following yesterday’s sharp 11.8% decline. • The upward move appears driven by...
🔴 Edesa Biotech is trading 10.5% down
Edesa Biotech is trading at $5.91, down 10.5% from a comparison close of $6.60 during regular trading. This is a price-action follow-up, so a separate catalyst...
🔴 Edesa Biotech is trading 5.5% down today amid low-liquidity volatility
Edesa Biotech is trading 5.5% down at $6.24 following recent volatility and a prior after-hours rebound. • There are no new company-specific headlines or...
🟢 Edesa Biotech is trading 5.4% up today despite no clear catalyst identified
Edesa Biotech is trading at $6.96 (5.4%) up in after-hours trading, rebounding from a recent pullback despite a lack of fresh company-specific headlines. •...
🟢 Edesa Biotech Inc is trading 7.57% up in after-hours
EDSA is trading at $7.25, up 7.57% in after-hours.
🟢 Edesa Biotech is trading 5.1% up today on positive Phase 3 ARDS data and $3.5M PIPE financing
Edesa Biotech is trading 5.1% up today at $7.16, extending its rebound from the July 13 close as investors react to recent clinical and financing...
🟢 Edesa Biotech is trading 5.3% up today on Phase 3 data and $3.5M PIPE financing
Edesa Biotech is trading 5.3% up at $7.17 in pre-market, extending its rebound from the July 13 close of $6.81. • The upward move follows continued positive...
🟢 Edesa Biotech is trading 6.6% up today on momentum from recent financing and Phase 3 data
Edesa Biotech is trading 6.6% up in after-hours trading at $7.26, rebounding from its regular-session close of $6.81. • The move follows continued positive...
🟢 Edesa Biotech Inc is trading 5.41% up in pre-market
EDSA is trading at $7.40, up 5.41% in pre-market.
🟢 EDSA is trading 6.5% up today following recent funding and clinical data momentum
EDSA is trading 6.5% up at $7.68 following recent funding and clinical data momentum, outperforming a broadly weaker U.S. market despite a lack of fresh...